Caris Life Sciences, Inc.

CAI · Nasdaq · ·

Compare

$23.96-2.2%Nov 12 close

Figures through September 30, 2026, from the 10-Q filed November 4, 2026

1W: -5.1%
1M: -20.8%

Caris Life Sciences, Inc. (CAI) stock — is it a good business? — InspectStocks

Caris Life Sciences, Inc.

CAI · Nasdaq · ·

Compare

$23.96-2.2%Nov 12 close

Figures through September 30, 2026, from the 10-Q filed November 4, 2026

1W: -5.1%
1M: -20.8%

Just reported

Q3 2026 results

From Caris Life Sciences's results release of November 4, 2026; its quarterly report has since been filed.

Revenue
Actual
$275.4M
+27% y/y
+4.4% q/q
Guided
—
No guide given
EPS, GAAP
Actual
$0.05
-38% y/y
Guided
—
No guide given
Operating income, GAAP
Actual
$19.3M
-41% y/y
-28% q/q
Guided
—
No guide given

Company outlook

Full year 2026

Revenue$1.04B – $1.05B+29% y/y Raised +1.0%

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.

Keep exploring

The themes Caris Life Sciences is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

Highest-graded in Biotechnology

Graded A or B and worth $2B or more: A first, then the largest.

All 355 graded companies in its industry

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

All grade rises

How it makes money

Molecular profiling services97%
Pharma research and development services4%

Shares of revenue are estimates for six months ended June 30, 2026, not figures from a filing.

Competes with

RHHBYFoundation Medicine (a Roche subsidiary)
TEMTempus AI
C
Size
$13.8B
Margin
-12.5%
GHGuardant Health
B
Size
$20.9B
Margin
-37.9%
NTRANatera
B
Size
$46.8B
Margin
-5.7%
GRALGRAIL
D
Size
$5.5B
Margin
-243.8%
PSNLPersonalis
D
Size
$1.7B
Margin
-147.7%

What it sells6

MI Profile
A cancer tissue test that examines DNA, RNA, and selected proteins, then gives doctors a report about the tumor that can help guide treatment choices.
Caris Assure
A blood test that examines tumor-related DNA and RNA in the blood and compares them with blood-cell DNA to help distinguish cancer changes from age-related blood-cell changes.
Caris Detect
A blood test designed to look for signs of multiple cancers, including cancers that may not yet have been found through symptoms or other tests.

Show 3 more

Caris ChromoSeq
A test of bone marrow or blood samples that examines DNA and RNA to help assess myeloid blood cancers, including acute myeloid leukemia and myelodysplastic syndromes.
Caris MI Clarity
A breast cancer test that examines digitized tissue-slide images and clinical information to estimate the chance of cancer returning at a distance from the original tumor.
FOLFIRSTai
A molecular signature included with certain cancer profiling results that helps doctors assess whether a patient with advanced colorectal cancer may benefit from particular chemotherapy combinations.

Who buys it4

Oncologists and other ordering physicians order tests for patients, often through hospitals, cancer centers, or medical groups.
Government and commercial health insurers pay for some patient tests when they cover the test and its use.
Biopharma companies pay for patient profiling, research support, and access to deidentified molecular and clinical data.
Academic cancer centers and researchers use Caris data and collaborate on cancer research.

What it stands on, and what could break it

What the business leans on

1Most revenue comes from clinical molecular profiling, particularly tissue-based profiling.
2Clinical testing revenue depends on government and commercial insurers covering tests and setting reimbursement rates; Medicare-covered cases generated 40.0% (six months ended June 30, 2026, high) of molecular profiling services revenue.
3Laboratory work relies on sequencing equipment and supplies from third-party suppliers, including Illumina and Roche.
4The company depends on laboratory capacity, sample transport and handling, and computing systems to process patient samples and deliver results.

What could go wrong

1A large share of current revenue comes from tissue-based profiling, so changes in test volumes or physician and patient adoption could affect the business.
2Insurers and government programs decide whether to cover tests and how much to reimburse; limited coverage or lower reimbursement could constrain testing and revenue.
3New and developing tests depend on validation, regulatory requirements, and payer decisions; delays or changes in these areas could prevent or limit their commercial use.

Full financial statements →

About Caris Life Sciences, Inc.

Caris analyzes DNA and RNA from cancer tissue and blood to find molecular features that may help doctors choose treatments. Its tests examine the whole exome—the protein-coding parts of DNA—or the whole transcriptome, and the company uses artificial intelligence (AI) and machine learning (ML) to interpret results. Caris also provides data and research services to drug companies and uses patient samples and data to investigate potential cancer drug targets.

Head office: Irving, Texas
Founded: 2008
Listed on: Nasdaq
Financial year ends: December 31

Built from Caris Life Sciences, Inc.’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.

Just reported